Gewinn- und Verlustrechnung von Illumina, Inc.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Empowered Funds LLC raised its stake in Illumina, Inc. (NASDAQ: ILMN) by 104.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,996 shares of the life sciences company's stock after purchasing an additional 6,633 shares during the period. Empowered

Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Illumina (ILMN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

The headline numbers for Illumina (ILMN) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Illumina, Inc. (ILMN) Q2 2026 Earnings Call Transcript

Illumina (ILMN) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.19 per share a year ago.

SAN DIEGO, July 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026. Second quarter 2026 results Revenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025 and up 8.1% excluding the impacts of currency, acquisitions, and China ("ROW1 organic revenue growth") GAAP operating margin of 21.1% and non-GAAP operating margin of 22.5% GAAP diluted EPS of $1.35 and non-GAAP diluted EPS of $1.31 "Illumina delivered strong results during the second quarter.